News Release: Capital Increase Reserved for employees outside France
26 Ottobre 2017 - 7:50AM
Capital Increase
Reserved for employees outside France
PDF Version of the news release
Charenton-le-Pont, France (October 26, 2017 - 8:00
a.m.) - Essilor International SA announces a capital
increase reserved for eligible employees of member companies of the
Group's International Employee Shareholding Plan.
Employee shareholding is central
to Essilor's history, identity and culture. On the eve of the
historic milestone created by the proposed combination with
Luxottica, this one-off employee shareholding plan in
14 countries is a key step towards achieving the Group's goal
of enabling one out of every two employees to become a shareholder.
It will be carried out subject to regulatory approval in certain
countries.
The Extraordinary Shareholders'
Meeting of May 11, 2017 authorized the Board of Directors
to increase the Company's capital up to a maximum of 1.5% of the
current capital through the issuance of new shares for the benefit
of employees and entities set up for employees of Group companies
located outside France.
The Board of Directors decided on
the principle and on the terms of the capital increase on
July 27, 2017 and delegated to the Chairman and Chief
Executive Officer the powers to implement the plan, within the
limit of a maximum of 200,000 shares and to decide the final
terms of the plan, in particular the subscription price of the new
shares.
The subscription price was set at
€103.24, corresponding to the average of the opening prices of the
Essilor International share on Euronext Paris over the
20 trading days preceding October 25, 2017 - the date on which
the dates of the subscription period and the subscription price
were set.
The subscription period will run
from October 27, 2017 to midnight CET on
November 20, 2017.
Employees will be able to
subscribe for the shares either through the "Essilor International
Relais 2017" employee shareholding fund -which will be
merged with the "Essilor International" employee shareholding fund-
or directly in some countries.
The new shares will immediately
rank pari passu with existing ordinary shares.
In particular, they will entitle their holders to any dividend
payments decided after their issuance. The admission of the new
shares to trading on Euronext Paris on the same listing line as the
existing shares (ISIN code: FR0000121667) will be requested as
soon as possible after the completion of the capital increase.
The new shares may not be sold for
three years, except in the early release cases provided for in the
International Employee Shareholding Plan.
This news release does not
constitute an offer to sell, nor a solicitation to buy Essilor
International shares. In the countries where authorizations must be
obtained or formalities (filing, disclosure, etc.) must be
fulfilled pursuant to the applicable regulations, eligible
employees will only be able to subscribe for the offer where such
authorizations have been obtained or such formalities have been
fulfilled within the required timeframes.
The shares described in this document have not been and will not be
registered with the US Securities and Exchange Commission and
may only be offered or sold in the United States as part of
transactions that are exempt from the registration requirements of
the US Securities Act of 1933.
This announcement constitutes the
information document required in accordance with Article 212-4
(5°) of the AMF's General Regulations and Article 19 of
Instruction No. 2016-04 and is published as a news release
pursuant to Article 221-3 of said General Regulations.
About Essilor
The world's leading ophthalmic optics company,
Essilor designs, manufactures and markets a wide range of lenses to
improve and protect eyesight. Its mission is to improve lives by
improving sight. To support this mission, Essilor allocates more
than €200 million to research and innovation every year, in a
commitment to continuously bring new, more effective products to
market. Its flagship brands are Varilux®,
Crizal®,
Transitions®,
EyezenTM,
Xperio®, Foster
Grant®,
BolonTM and
Costa®. It also
develops and markets equipment, instruments and services for
eyecare professionals.
Essilor reported consolidated revenue of more than
€7.1 billion in 2016 and employs approximately 64,000 people
worldwide. It markets its products in more than 100 countries and
has 33 plants, 490 prescription laboratories and edging facilities,
as well as 5 research and development centers around the world (as
of December 31, 2016). For more information, please visit
www.essilor.com.
The Essilor share trades on the Euronext Paris
market and is included in the Euro Stoxx 50 and CAC 40
indices.
Codes and symbols: ISIN: FR0000121667; Reuters:
ESSI.PA; Bloomberg: EI:FP.
------------------------
Investor Relations
and Financial Communications
Phone: +33 (0)1 49 77 42 16
PDF Version of the news
release
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Essilor International via Globenewswire